From: Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis
Univariate | Multivariate | |||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Conversion | ||||
RNS (+) | 7.462 (1.651–33.718) | 0.009* | 6.007 (1.316–27.412) | 0.021* |
Anti-AchR Ab (+) | 6.428 (0.832–49.681) | 0.075 | ||
B2/B3 thymoma versus Hyperplasia + AB/B1 thymoma | 5.987 (1.325–27.044) | 0.020* | 4.611 (1.010–21.043) | 0.048* |
CSR | ||||
Onset age > 60 versus ≤ 60 | 0.230 (0.052–1.011) | 0.052 | ||
RNS (+) | 0.378 (0.122–1.175) | 0.093 | ||
Anti-AchR Ab (+) | 0.396 (0.147–1.068) | 0.067 | ||
Stage II/III thymoma versus Hyperplasia + stage I thymoma | 0.300 (0.104–0.864) | 0.026* | 0.300 (0.104–0.864) | 0.026* |